At long last, the eClinical industry is showing signs of evolving beyond the challenges that stem from traditional pricing models and workflows.
Here’s a scenario you may find familiar if you’re a veteran eClinical technology user: During your vendor selection process, you’re in discussions with a company that promises a monthly subscription cost significantly lower than any of the other vendors you’ve considered. The vendor promises a fast study build, an intuitive interface, and all the additional modules you may need. You can’t deny it – it sounds like a pretty great deal. But as the saying goes: If something sounds too good to be true, it probably is.
Let’s say you move forward with this vendor, and implement their electronic data capture (EDC) for your next clinical trial. Before long, all sorts of extra costs, previously unseen, have emerged:
In a break from scenarios like the one just described, some industry players are moving toward a more common-sense approach to pricing and workflow design in eClinical technology. This shift is driven by a few common-sense principles: Shouldn’t clinical research remain in the hands of clinical researchers? Shouldn’t eClinical software pricing be simple and transparent, so that sponsors and CROs can better quantify the investment they’re making?
We’ve always seen our work, at Medrio, less about the capabilities of our software than about the capabilities of those who use it. We believe that any EDC should acknowledge, and cater to, a few fundamental rights of EDC users:
The right to full control – Users should be able to perform their essential functions independent of other parties. They should be able to handle study build and mid-study changes in-house.
The right to administrative flexibility – eClinical users often have to deal with a host of complexities before data management even begins, from pricing to training, to onboarding and beyond. These processes should be as simple as possible so that researchers can actually get to work on their research.
When users can manage their tasks in-house and benefit from administrative efficiency, their work, across the board, becomes a lot simpler – and from that simplicity flow the high speed and low costs that today’s early-phase pharma, device, and diagnostics trials demand. After all, the fundamental goals of eClinical technology are to reduce costs and accelerate timelines – and by imposing hidden fees and creating dependence on external parties, an EDC company truly defeats its own purpose.